Blood cancer therapy PKC412 shows promise in EBS cells
Summary by Epidermolysis Bullosa News
1 Articles
1 Articles
Blood cancer therapy PKC412 shows promise in EBS cells
PKC412, a medication already used for treating certain blood cancers, has the potential to be repurposed for treating epidermolysis bullosa simplex (EBS), according to a preclinical study. Using skin cells from people with various EBS-causing genetic mutations, scientists found that PKC412, also known as midostaurin, made the cells more resilient against stress and damage. In a newly developed three-dimensional (3D) EBS skin model, the treatment…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium